Solid Tumor Clinical Trials

 

St. Jude Clinical Trials

AOST1421: Combination Drug Therapy to Treat Patients with Recurrent Osteosarcoma

Diseases Treated:

Osteosarcoma

Eligibility:

  • Younger than 30 years old
  • Original diagnosis of osteosarcoma
  • Osteosarcoma has come back in the lungs after original treatment
  • Lung tumors have been removed surgically within the last 4 weeks before enrolling in the study
View Trial

ASCIST: Donor Natural Killer Cell Infusion after Autologous CD133+ Selected Stem Cell Transplant in Treating Younger Patients with High-Risk Solid Tumors or Lymphomas

Diseases Treated:

High-risk solid tumors and lymphomas

Eligibility:

  • Has a type of high-risk cancer including
    • Neuroblastoma
    • Solid tumors
    • Lymphomas
  • 21 years of age or younger
  • Has not received a prior hematopoietic (blood cells from bone marrow) stem cell transplant within the previous three months
View Trial

BMNIRN: Talazoparib Plus Irinotecan With or Without Temozolomide in Children with Refractory or Recurrent Solid Malignancies

Diseases Treated:

Relapsed or refractory solid tumors

Eligibility:

  • Participant has refractory or recurrent solid tumor for which there is no standard therapy.
  • Participant has had histologic verification of malignancy at original diagnosis or at the time of relapse.
  • Participant is twelve (12) months to twenty-five (25) years of age at the time of enrollment on study.
  • Participant life expectancy is at least eight (8) weeks. 
View Trial

iRET: Intravitreal Chemotherapy for Children with Retinoblastoma

Diseases Treated:

Retinoblastoma

Eligibility:

  • Age 17 or younger
  • Diagnosis of retinoblastoma that did not go away with treatment or came back after treatment
View Trial

MEKPEM: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced Relapsed or Refractory Solid Tumor or Lymphoma

Diseases Treated:

Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma

Eligibility:

  • Participant has advanced melanoma or PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma
  • Participant of child bearing potential has a negative pregnancy test 72 hours prior to medication administration
  • Participant has appropriate liver and kidney function
View Trial

NB2012: Therapy for Children with Advanced Stage High-Risk Neuroblastoma

Diseases Treated:

Neuroblastoma

Eligibility:

  • Participant is < 19 years of age at the time of study enrollment.
  • Participant has newly diagnosed, advanced stage, high-risk neuroblastoma.
  • Participant has histologic proof of neuroblastoma or positive bone marrow for tumor cells with increased urine catecholamine.
  • Participant has adequate renal and hepatic function.
View Trial

RADIANT: Donor Hematopoietic Stem Cell Transplant in Treating Young Patients with Relapsed or Refractory Solid Tumors or Lymphomas

Diseases Treated:

Relapsed or refractory solid tumors or lymphomas

Eligibility:

  • Between the ages of 2 and 21 years
  • Solid tumor or lymphoma as primary cancer
  • Cancer that has come back or did not respond to previous chemotherapy
  • No heart, kidney or liver problems
View Trial

RMS13: Chemotherapy, Surgery, and Radiation Therapy in Treating Patients with Newly Diagnosed, Localized Rhabdomyosarcoma

Diseases Treated:

Rhabdomyosarcoma (low-risk, intermediate-risk and high-risk)

Eligibility:

  • Must have newly diagnosed rhabdomyosarcoma
  • Less than 22 years of age
  • Has not received previous treatment with chemotherapy or radiation therapy
View Trial

SJATRT: Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

Diseases Treated:

Brain Tumor : Recurrent, progressive, or newly diagnosed atypical teratoid rhabdoid brain tumors (ATRT)
Solid Tumor : Progressive extra-CNS malignant rhabdoid solid tumors (MRT)

Eligibility:

  • Has one of these types of tumors:
    • Newly diagnosed atypical teratoid rhabdoid tumors (ATRTs) or synchronous extraneural ATRTs
    • ATRTs or malignant rhabdoid tumors (MRTs) that have come back after previous treatment (recurrent disease)
    • ATRTs or MRTs that are growing after previous treatment (progressive disease)
  • 21 years of age or younger
View Trial

SJRET6: Combination Chemotherapy in Treating Patients with Newly Diagnosed, Previously Untreated Intraocular Retinoblastoma

Diseases Treated:

Retinoblastoma

Eligibility:

  • Newly diagnosed retinoblastoma that has not spread beyond the eye
  • Has not received previous treatment with chemotherapy or radiation therapy
  • Patients who have been diagnosed with retinoblastoma in one eye who did not receive chemotherapy, but then developed retinoblastoma in the opposite eye
View Trial

Collaborative Clinical Trials

A031102: Standard-Dose Combination Chemotherapy Compared to High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Diseases Treated:

Germ cell tumors

Eligibility:

  • 14 years old or older
  • Diagnosis of germ cell tumor (GCT)
  • Previously received 3 to 6 cycles of cisplatin-based chemotherapy
  • No more than one prior line of chemotherapy
  • No prior treatment with high-dose chemotherapy
View Trial

ADV1212: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Diseases Treated:

Relapsed or refractory solid tumors or anaplastic large cell lymphoma

Eligibility:

  • Participant is > than 12 month and < 21 years of age at the time of enrollment.
  • Participant has histologic verification at original diagnosis or relapse or relapse of relapsed or refractory solid tumor or anaplastic large cell lymphoma (ALCL).
  • Participant does not have primary or metastatic CNS tumor.
  • Participant has not received prior therapy with crizotinib.
View Trial

ADV1312: WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Diseases Treated:

Relapsed or refractory solid tumors

Eligibility:

  • Participant is >12 months and < 21 years of age at the time of study entry.
  • Participant has had histologic verification of malignancy at original diagnosis or relapse.
  • Participant has serum tumor markers including alpha-fetoprotein or beta-HCG.
  • Participant has a relapsed or refractory solid tumor.
View Trial

ADV1414: Phase I Study of Selinexor to Treat Patients with Recurrent and Refractory Pediatric Solid Tumors

Diseases Treated:

Solid Tumors

Eligibility:

  • Diagnosis of solid tumor that is resistant to other anticancer therapy or has come back after therapy. Includes lymphoma and central nervous system (CNS) tumors that may or may not require surgery.
  • Fully recovered from the acute toxic effects of all prior anticancer therapy
  • At least 1 but not more than 21 years of age
  • Able to swallow tablets whole
View Trial

BRF116: A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Diseases Treated:

Solid tumors, giomas, hystiocytosis

Eligibility:

  • Participant is greater or equal to 12 months and less than 18 years at the time of signing the informed consent form.
  • Participant has BRAF V600 mutation positive tumor as confirmed in a CLIA-approved laboratory or equivalent
  • Participant has recurrent disease, refractory disease, or progressive disease after having received at least one standard therapy for their disease, OR participant has metastatic (or surgically unresectable) melanoma, and is being enrolled for first-line treatment. Melanoma participants with CNS involvement may be enrolled.
View Trial

EZH102: Tazemetostat in Children and Young Adults with Synovial Sarcoma or INI1-Negative Tumors

Diseases Treated:

Eligibility:

  • Between 6 months and 21 years old
  • Relapsed or refractory rhabdoid tumors, INI1-negative tumors or synovial sarcoma
View Trial

LDKALK: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Diseases Treated:

Refractory or progressive malignancies

Eligibility:

  • Age > 12 months and < 18 years.
  • Participant has been diagnosed with a locally advanced or metastatic malignancy that has progressed despite standard therapy, or which no effective standard therapy exists.
  • Specimen is being submitted for molecular pre-screening to test for genetic alteration of ALK and the tumor must carry a genetic alteration of the ALK gene.
  • Participant has adequate liver, kidney, cardiac, and bone marrow function.
View Trial

MEK116: Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Diseases Treated:

Relapsed or refractory solid tumor

Eligibility:

  • Participant is at least one month old and younger than 18 years old at the time of signing the informed consent (in Part A, participants < 2 years of age are not included).
  • Participant has a histologically confirmed solid tumor
  • Participant has a disease that is relapsed or refractory to all potentially curative standard treatment regimens, or has a disease for which there is no standard treatment regimen that is potentially curative.
View Trial

NBL1232: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-High Risk Neuroblastoma

Diseases Treated:

Neuroblastoma, ganglioneuroblastoma

Eligibility:

  • Participant has been enrolled on ANBLB1 (ANBL00B1).
  • Participant has newly diagnosed MYCN non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma.
  • Participant is less than 12 months (Group A) and less than 18 months (Group B and Group C) of age at diagnosis.

 

View Trial

REFGCT: A Phase II Study of Two Drugs for Relapsed or Refractory Malignant Germ Cell Tumors

Diseases Treated:

Refractory and recurrent solid tumors

Eligibility:

  • Participant is between 1-25 years old e at the time of enrollment (Note:  eligibility up to age 50 years for other participating sites).
  • Participant has had histologic verification of an extracranial germ cell tumor that is not a pure teratoma (mature or immature), pure germinoma, or pure seminoma.
  • Participant has relapsed or refractory disease following at least two prior platinum-containing chemotherapy regimens.
  • Patients must have measurable disease, documented according to RECIST criteria, or evaluable disease with a standard tumor marker (AFP and/or HCG) greater than 10 times the upper limit of normal.
  • Other requirements for this study.
View Trial

RST1321: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery

Diseases Treated:

Non-rhabdomyosarcoma soft tissue sarcoma

Eligibility:

  • > 2 years at the time of the biopsy that established the diagnosis of NRSTS.
  • Participant has a NRSTS in the extremity or trunk.
  • Participant has adequate bone marrow function.
  • Participant has not had prior Anthracycline or Ifosfamide therapy.
  • Participant is not HIV-positive.
View Trial

SBRT1: Stereotactic Radiation Therapy for Pediatric Sarcomas

Diseases Treated:

Metastatic sarcomas

Eligibility:

  • Participant has histologically or cytologically confirmed diagnosis:
    • Nonrhabdomyosarcoma of soft tissue
    • Ewing sarcoma
    • Osteosarcoma at any site
  • Participant must be greater than 3 years of age and < 40 years of age.
  • Participant has not had any prior radiotherapy to the treatment site.
View Trial